Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) is set to release its earnings data before the market opens on Wednesday, August 9th. Analysts expect Progenics Pharmaceuticals to post earnings of ($0.20) per share for the quarter.

Progenics Pharmaceuticals Inc. (PGNX) opened at 5.82 on Monday. Progenics Pharmaceuticals Inc. has a 12 month low of $4.84 and a 12 month high of $11.72. The stock has a 50 day moving average price of $6.81 and a 200 day moving average price of $8.35. The stock has a market capitalization of $408.71 million, a PE ratio of 60.00 and a beta of 3.35.

A number of equities analysts recently commented on PGNX shares. Jefferies Group LLC reaffirmed a “buy” rating and issued a $12.00 target price on shares of Progenics Pharmaceuticals in a report on Thursday, June 8th. TheStreet cut Progenics Pharmaceuticals from a “c” rating to a “d+” rating in a report on Friday, May 26th. Zacks Investment Research raised Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, June 6th. Cantor Fitzgerald started coverage on Progenics Pharmaceuticals in a report on Wednesday, July 12th. They issued an “overweight” rating and a $15.00 target price on the stock. Finally, ValuEngine cut Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $12.33.

COPYRIGHT VIOLATION NOTICE: “Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) Set to Announce Quarterly Earnings on Wednesday” was reported by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/08/07/progenics-pharmaceuticals-inc-nasdaqpgnx-set-to-announce-quarterly-earnings-on-wednesday.html.

About Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.

Earnings History for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.